RCEL
Q4 2026 EPS Estimate
$-0.24
Nov 5, 2026 · Reports after close
Revenue Estimate
$22M
FY2028E EPS$0.03
FY2029E EPS$2.76

Analyst Sentiment

Wall St. Consensus
Buy
8 analysts·Limited coverage
72
Score
7 Buy (88%)1 Hold (13%)0 Sell (-1%)
Rating Breakdown
Strong Buy
00%
Buy
788%
Hold
113%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$6.00
-40.4%
Consensus
$10.00
-0.6%
Bull
$11.00
+9.3%
12-Month Target Range8 analysts
$6.00$10.00$11.00
Current $10.06Consensus
Current Price
$10.06
Above Consensus
$0.06

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+25.83%
EPS
FY2028
Rev+21.66%
EPS
FY2029
Rev+207.11%
EPS+9406.42%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$88M$110M$134M$411M$498M
Low$84M$105M$128M$394M$476M
High$92M$116M$143M$432M$522M
EBITDA Avg$-63M$-79M$-96M$-296M$-358M
Low$-66M$-83M$-103M$-311M$-376M
High$-60M$-76M$-92M$-283M$-343M
EBIT Avg$-65M$-81M$-99M$-304M$-368M
Low$-68M$-86M$-106M$-319M$-386M
High$-62M$-78M$-95M$-291M$-352M
Net Income Avg$-26M$-11M$3M$77M$101M
Low$-28M$-11M$-2M$73M$95M
High$-25M$-10M$4M$82M$107M
EPS Avg$-0.95$-0.38$0.03$2.76$3.62
Low$-1.01$-0.41$-0.06$2.60$3.42
High$-0.89$-0.36$0.14$2.94$3.85
Analysts (Rev / EPS)5 / 35 / 36 / 34 / 13 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$22M$24M$25M$28M$28M$30M$30M$31M
Low$22M$23M$25M$27M$28M$30M$29M$30M
High$23M$25M$26M$28M$29M$31M$30M$31M
EBITDA Avg$-16M$-17M$-18M$-20M$-20M$-22M$-21M$-22M
Low$-16M$-18M$-18M$-20M$-21M$-22M$-22M$-23M
High$-16M$-17M$-18M$-20M$-20M$-21M$-21M$-22M
EBIT Avg$-17M$-18M$-19M$-20M$-21M$-22M$-22M$-23M
Low$-17M$-18M$-19M$-21M$-21M$-23M$-22M$-23M
High$-16M$-17M$-18M$-20M$-21M$-22M$-22M$-22M
Net Income Avg$-7M$-6M$-6M$-5M$-4M$-4M$-5M$-5M
Low$-8M$-7M$-6M$-5M$-4M$-4M$-5M$-5M
High$-7M$-4M$-6M$-5M$-4M$-4M$-5M$-5M
EPS Avg$-0.24$-0.19$-0.19$-0.15$-0.14$-0.12$-0.16$-0.16
Low$-0.24$-0.24$-0.19$-0.15$-0.14$-0.13$-0.16$-0.17
High$-0.23$-0.12$-0.19$-0.15$-0.13$-0.12$-0.15$-0.16
Analysts (Rev / EPS)3 / 25 / 44 / 14 / 14 / 14 / 13 / 23 / 2

Earnings Surprises

Recent Analyst Actions

Aug 19, 2026BTIG
Avita Medical Ltd. (RCEL) PT Raised to $11 at BTIG
Target:$11.00
+11.7%from $9.85
Aug 7, 2026BTIG
BTIG Upgrades Avita Medical Ltd. (RCEL) to Buy
Target:$7.00
+47.4%from $4.75
May 15, 2026Lake Street
Avita Medical upgraded to Buy from Hold at Lake Street
Target:$6.00
+37.6%from $4.36
Mar 26, 2026Northland Securities
Avita Medical stock pullback creates buying opportunity, says Northland
Target:$10.00
+159.1%from $3.86
Jan 16, 2026Lake Street
Avita Medical price target raised to $3.50 from $3 at Lake Street
Target:$3.50
-2.6%from $3.60
Oct 17, 2025Lake Street
Avita Medical downgraded to Hold from Buy at Lake Street
Target:$4.00
-25.7%from $5.38
Jan 8, 2025Lake Street
Avita Medical price target lowered to $14 from $20 at Lake Street
Target:$14.00
-0.4%from $14.06
May 14, 2024Piper Sandler
Piper Sandler Downgrades Avita Medical Ltd. (RCEL) to Neutral
Target:$9.00
+7.8%from $8.35
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.